Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
BOSTON, Aug. 15, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier (BBB)-crossing platform technology to address challenging disease areas with high unmet need.
- "Our commitment to the development of new treatment options for people living with lysosomal storage disorders (LSD) is global, as evidenced by recent regulatory approvals," said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
- We are especially proud to advance this important research with Aliada, a partner with vast experience in neuro drug development and biologics delivery."
- Founded in 2021, Aliada leverages its MODEL platform to research and develop differentiated large molecule therapeutics for patients with neurological disorders and systemic disorders with CNS involvement.
- This collaboration will allow Aliada to demonstrate the diverse capabilities of our MODEL platform, which enables us to efficiently transport a diverse range of therapeutic cargoes into the brain."